Arkansas Clinical Trials Report — May 2026

For Arkansans considering participation in clinical research, May 2026 presents a crucial period, especially for those looking to join studies that are nearing their enrollment deadlines. Across the state, 46 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 5 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, heart conditions, and neurological disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage IV lung cancer AJCC V8
• Advanced lung non-small cell carcinoma
• Asthma
• Ambulatory heart failure, NYHA Class IV
• Anatomic stage II breast cancer AJCC V8
• Anatomic stage III breast cancer AJCC V8
• Advanced solid tumor
• Attention-deficit/hyperactivity disorder
• Bipolar disorder, manic
• Blood pressure

Major Research Initiatives Launch in Arkansas

This month brings two significant new trials to Arkansas, both from a major pharmaceutical sponsor. These Phase 3 studies offer participants the chance to engage with cutting-edge treatments for metabolic and cardiovascular conditions, highlighting the state's role in advancing medical science.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.

Both of these new trials are drug-focused and are industry-sponsored, indicating a strong commitment from pharmaceutical companies to address widespread health challenges. They also include older adults in their eligibility criteria, ensuring that a broad age range can participate.

Arkansas's Evolving Research Landscape

This month, Arkansas saw the opening of 2 new clinical trials, a notable decrease compared to the 5 trials that launched in April 2026, and significantly fewer than the 13 in March, 14 in February, 16 in January, or 22 in December 2025. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 671 clinical trials currently recruiting across 35 cities and 329 research sites.

The new research initiatives this month are concentrated in a single metropolitan area, with both new trials opening in Little Rock. This indicates that while opportunities are available statewide, the capital city remains a central hub for new clinical research. The conditions targeted by these new studies are:

• Obesity
• Heart failure
• Type 2 diabetes

These conditions represent significant public health concerns, and the new trials offer potential new treatment avenues for individuals affected by them.

Participation Opportunities: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 2 new trials launched this month, both include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. There are no new trials specifically for children, or female-only or male-only populations this month.

For individuals without a specific medical condition, opportunities to contribute are still available. While neither of the new trials this month is actively seeking healthy volunteers, there are still 48 clinical trials across Arkansas that are currently recruiting healthy participants. This provides numerous avenues for those interested in supporting medical research without having a diagnosed condition.

As we look ahead, the focus will likely remain on the ongoing enrollment in these significant Phase 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Arkansas. Individuals interested in participating, especially those for whom trials are closing soon, are encouraged to act quickly to explore their options.